Egrifta (Tesamorelin) Switching Protocols: How to Switch From or To Other Drugs in Class

How Tesamorelin Works: Mechanism at the Pituitary Level

Tesamorelin is a synthetic 44-amino-acid analogue of endogenous GHRH, extended by a trans-3-hexenoic acid group at the N-terminus that slows enzymatic degradation [1]. It binds the pituitary GHRH receptor with high specificity, triggering a cAMP-mediated cascade that increases GH gene transcription and promotes pulsatile GH secretion. The result is a physiologic, pulsatile GH release pattern rather than the supraphysiologic continuous exposure seen with exogenous recombinant human GH (rhGH).

Why Pulsatile GH Matters Clinically

Pulsatile release preserves the normal GH-IGF-1 feedback axis. IGF-1 rises proportionally to GH secretion and signals the hypothalamus to reduce GHRH output, which limits over-suppression of the axis. This self-limiting mechanism is one reason tesamorelin carries a lower risk of IGF-1 excess compared with direct rhGH administration [2].

Downstream Metabolic Effects

GH acts on hepatic GH receptors to increase IGF-1 synthesis and on adipocytes to stimulate lipolysis through hormone-sensitive lipase. In HIV-associated lipodystrophy, visceral adipose tissue (VAT) accumulates because antiretroviral therapy (particularly older thymidine analogues and protease inhibitors) suppresses endogenous GH pulsatility. Tesamorelin partially restores that pulsatility, driving preferential visceral fat reduction [3].

In the key phase 3 trial by Falutz et al. (N=412), 26 weeks of tesamorelin 2 mg/day produced a 15.2% reduction in VAT by CT scan compared with a 4.8% increase in the placebo group (P<0.001) [1]. A subsequent 26-week extension confirmed that VAT reduction was maintained at 52 weeks, with a mean net difference of approximately 18 cm² versus placebo on cross-sectional CT [4].

The Drug Class: GHRH Analogues and GH Secretagogues

Tesamorelin belongs to the GHRH analogue subclass of GH secretagogues. Understanding the broader class is necessary before designing a switch protocol.

GHRH Analogues

Sermorelin (GHRH 1 to 29) was the first synthetic GHRH fragment approved in the United States for pediatric GH deficiency diagnosis; it lost FDA approval for that indication in 2008 but remains available through compounding pharmacies [5]. Its plasma half-life is roughly 10 to 12 minutes, shorter than tesamorelin's 26 to 38 minutes, because it lacks the stabilizing N-terminal modification.

CJC-1295 is a synthetic GHRH analogue conjugated to a drug affinity complex (DAC) that binds albumin and extends half-life to 6 to 8 days. It is not FDA-approved and is available only through compounding. The extended half-life produces more tonic, less pulsatile GH release, which may blunt the physiologic feedback advantages seen with tesamorelin.

Modified GRF (1 to 29) (also called "Mod GRF 1 to 29") is another compounded peptide with a half-life of approximately 30 minutes. It is pharmacologically similar to tesamorelin but lacks clinical trial data in any FDA-reviewed dataset.

Ghrelin Mimetics (GHRPs)

GH-releasing peptides (GHRPs) such as ipamorelin, GHRP-2, and GHRP-6 act on the ghrelin receptor (GHSR-1a) rather than the GHRH receptor. They can be combined with GHRH analogues for additive GH release because the two pathways converge at the somatotroph through different second-messenger systems [6]. This mechanistic difference is clinically relevant: switching from a GHRP to tesamorelin is not a simple class substitution; it changes receptor targets entirely.

Recombinant Human GH

RhGH (somatropin) bypasses the pituitary entirely and delivers GH directly to systemic receptors. Because it provides continuous exogenous GH rather than stimulating endogenous pulses, switching from tesamorelin to rhGH suppresses the hypothalamic-pituitary axis and eliminates the self-regulating IGF-1 feedback loop described above [2].

Pharmacokinetic Rationale for Washout Timing

A washout period before switching allows pituitary GHRH receptors to resensitize and IGF-1 levels to return toward pre-treatment baseline. The key parameters are:

• Tesamorelin terminal half-life: 26 to 38 minutes. The peptide itself clears plasma within 3 to 4 hours of injection [7].
• IGF-1 normalization: IGF-1 peaks 8 to 24 hours after each tesamorelin dose and begins declining within 48 to 72 hours of the last injection, reaching near-baseline in 5 to 7 days in most patients.
• Pituitary receptor resensitization: Animal data suggest GHRH receptor expression upregulates within 7 to 14 days after agonist withdrawal, though human data are limited [8].

Based on these parameters, a 1-week minimum washout is reasonable before initiating any GH secretagogue with the same receptor target, and a 2-week washout provides additional safety margin if switching to a compound with a different mechanism (e.g., from tesamorelin to a GHRP, or to rhGH).

Switching FROM Tesamorelin to Other Agents

To Sermorelin (Compounded)

Sermorelin targets the same GHRH receptor, making this the most pharmacologically similar switch. A 7-day washout is generally sufficient. Start sermorelin at 200 to 300 mcg subcutaneously once daily (or split twice daily given its shorter half-life) and recheck IGF-1 at 4 weeks. The primary clinical concern is efficacy loss: no published data confirm that sermorelin produces equivalent VAT reduction in HIV-associated lipodystrophy, and the FDA has not reviewed it for this indication.

To CJC-1295 (Compounded, with DAC)

CJC-1295 DAC's 6-to-8-day half-life means that IGF-1 may accumulate with weekly dosing. After stopping tesamorelin, wait 10 to 14 days before the first CJC-1295 DAC injection to avoid additive IGF-1 elevation during overlap. Dose CJC-1295 DAC at 1 to 2 mg subcutaneously weekly. Monitor IGF-1 at 4 weeks; if IGF-1 exceeds the upper limit of the age-adjusted normal range, reduce to biweekly dosing.

To Ipamorelin or GHRP-2 (Compounded GHRPs)

Because GHRPs act on GHSR-1a rather than the GHRH receptor, receptor-level overlap is minimal. A 5 to 7 day washout from tesamorelin is sufficient before starting ipamorelin 100 to 300 mcg subcutaneously two to three times daily. Combining a GHRP with a low-dose GHRH analogue later (stacking) may be considered for patients who need broader GH axis stimulation, but IGF-1 must be monitored every 4 weeks during titration [6].

To Recombinant Human GH (Somatropin)

This switch represents the largest mechanistic step. After stopping tesamorelin, allow 14 days before starting rhGH to let endogenous GH pulsatility partially recover. Typical starting doses of somatropin in adult HIV patients range from 0.1 to 0.4 mg/day subcutaneously, titrated by IGF-1 [9]. The Endocrine Society's 2011 Clinical Practice Guideline on adult GH deficiency notes that IGF-1 should be maintained in the middle tertile of the age- and sex-adjusted normal range during rhGH therapy [9].

"The goal of GH replacement in adults is to normalize IGF-1 concentrations, not to maximize GH secretion," states the 2011 Endocrine Society guideline, emphasizing that dose titration should target biochemical normalization rather than symptom surrogates [9].

Switching TO Tesamorelin From Other Agents

From Sermorelin or Mod GRF (1 to 29)

Allow 5 to 7 days after the last sermorelin or Mod GRF dose. Start tesamorelin at the standard 2 mg once daily. Draw IGF-1 at 4 weeks. Because tesamorelin has a longer effective duration of action than sermorelin, patients switching from twice-daily sermorelin to once-daily tesamorelin may notice more consistent morning IGF-1 levels.

From CJC-1295 DAC

CJC-1295 DAC's long half-life requires a longer washout before tesamorelin initiation. The last CJC-1295 DAC injection should precede tesamorelin by at least 14 to 21 days to avoid sustained GHRH receptor occupancy that could blunt tesamorelin's pulsatile stimulus. Check IGF-1 before starting; if it remains above the upper normal range at day 14 post-last-injection, extend the washout to day 21.

From Ipamorelin or GHRP-6

A 5-day washout is adequate given the short half-lives (ipamorelin half-life approximately 2 hours). Start tesamorelin at 2 mg once daily on day 6. Some clinicians continue a low-dose GHRP (ipamorelin 100 mcg at bedtime) alongside tesamorelin to preserve the nocturnal GH pulse, though this combination has not been evaluated in a randomized trial.

From Recombinant Human GH

Stopping exogenous rhGH causes a predictable fall in IGF-1 over 7 to 14 days as the liver loses its direct GH stimulus. Wait at least 14 days after the last rhGH injection before initiating tesamorelin so that the pituitary GHRH receptor is no longer suppressed by chronically elevated IGF-1 feedback. A baseline IGF-1 drawn on the day tesamorelin starts confirms adequate washout. If IGF-1 is still above the upper limit of normal at day 14, extend the washout to day 21 and recheck.

Monitoring Framework After Any Switch

The table below organizes minimum monitoring requirements after any tesamorelin switch. Clinicians should individualize based on patient-specific IGF-1 trajectory and symptom burden.

| Timepoint | Test | Action Threshold | |---|---|---| | Day 0 (switch day) | IGF-1, fasting glucose, HbA1c | Establish baseline; defer switch if IGF-1 > ULN | | Week 4 | IGF-1 | Dose adjustment if IGF-1 <LLN or >ULN | | Week 12 | IGF-1, fasting glucose, VAT (optional CT) | Confirm VAT response; recheck glucose tolerance | | Month 6 | IGF-1, fasting glucose, HbA1c, lipid panel | Ongoing safety screen | | Month 12 and annually | Full metabolic panel, IGF-1, body composition | Assess sustained benefit |

ULN = upper limit of normal; LLN = lower limit of normal for age- and sex-adjusted reference range.

Glucose Monitoring During and After Switching

Both tesamorelin and rhGH reduce insulin sensitivity. In Falutz et al., fasting blood glucose increased modestly in the tesamorelin arm, though HbA1c changes were not statistically different from placebo at 26 weeks [1]. Patients with pre-existing type 2 diabetes or HbA1c above 7% should have glucose checked at 2 weeks after any GH axis drug switch, not only at the standard 4-week mark. The FDA label for Egrifta carries a specific warning about glucose intolerance and new-onset diabetes [10].

Managing IGF-1 Excursions

If IGF-1 exceeds 1.3 times the upper limit of the age-adjusted normal range on any GH secretagogue, the recommended response is dose reduction rather than immediate cessation, unless symptoms of GH excess (arthralgia, peripheral edema, carpal tunnel syndrome) are present. In clinical practice, reducing tesamorelin to 1 mg every other day while rechecking IGF-1 in 3 weeks is a reasonable strategy before full discontinuation.

Special Populations: HIV-Specific Considerations

HIV-positive patients on modern antiretroviral therapy (ART) present unique switching challenges because ART itself affects GH axis function and lipid metabolism.

Antiretroviral Drug Interactions

Protease inhibitors (particularly ritonavir-boosted regimens) induce CYP3A4 and may accelerate metabolism of some compounded peptides. Tesamorelin, however, is a peptide cleaved by dipeptidyl peptidase IV (DPP-IV) and endopeptidases rather than cytochrome P450 enzymes, which means CYP-based drug interactions are not a primary concern [7]. When switching to non-peptide GH secretagogues or rhGH, CYP3A4 induction by ritonavir may reduce effective drug exposure and should be factored into dosing.

CD4 Count and Immune Status

There is no established minimum CD4 threshold for tesamorelin use, but the FDA label excludes patients with active malignancy, and clinicians should be cautious in patients with CD4 counts below 200 cells/mm³ who are at higher risk for opportunistic malignancy. Before switching any patient with low CD4 count to a GH-stimulating regimen, confirm no active lymphoma or Kaposi sarcoma [10].

ART Regimen Stability

A switch in the GH axis drug should not be simultaneous with an ART regimen change. Separating the two changes by at least 4 weeks allows clinicians to attribute any metabolic shift to the correct drug. Falutz et al. Required a stable ART regimen for at least 8 weeks before enrollment [1], setting a practical precedent for clinical practice.

Discontinuation of Tesamorelin: What Happens

VAT returns toward baseline within 12 weeks of stopping tesamorelin. In the randomized withdrawal phase of the Falutz 2010 extension study (N=246), patients re-randomized to placebo after 26 weeks of active treatment showed VAT rebound to near-baseline levels by week 52, while those continuing tesamorelin maintained their VAT reduction [4]. This rebound effect is critical to communicate to patients: tesamorelin is a maintenance therapy, not a cure.

Pituitary function recovers promptly. Endogenous GH pulsatility, assessed by overnight GH sampling, returns to pre-treatment patterns within 2 to 4 weeks of stopping tesamorelin based on the drug's short half-life and the self-limiting IGF-1 feedback axis [7]. This rapid recovery makes tesamorelin substantially easier to stop and restart than rhGH, which can suppress endogenous GH secretion more persistently.

Practical Prescribing Steps for a Tesamorelin Switch

1. Draw IGF-1, fasting glucose, and HbA1c on the day of the planned switch decision.
2. Complete the appropriate washout (5 to 14 days depending on the prior agent; see section above).
3. Confirm IGF-1 is within the normal range before starting the new drug.
4. Initiate tesamorelin at 2 mg subcutaneously once daily in the evening (or the new agent per its standard starting dose).
5. Recheck IGF-1 and fasting glucose at 4 weeks.
6. Adjust dose if IGF-1 is out of range; maintain stable dose if within range.
7. Obtain CT or DEXA body composition assessment at 12 weeks to confirm VAT response.
8. Document ART regimen stability; do not co-time the GH axis switch with an ART change.

"The primary measure of efficacy in HIV lipodystrophy trials has been visceral fat by CT, not patient-reported outcomes or anthropometric surrogates," the Endocrine Society's Hormone Foundation has noted in its patient guidance materials, underscoring why objective body composition tracking is part of standard monitoring [9].